Maxcyte Inc (MXCT)

Apr 04, 2026

MXCT PE Ratio & Valuation, Is MXCT Overvalued - Intellectia AI

Apr 04, 2026

Apr 04, 2026

MXCT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 04, 2026

Apr 04, 2026

MaxCyte (MXCT) price target decreased by 14.88% to 4.90 - MSN

Apr 04, 2026

Apr 02, 2026

Big Money Moves: Is MaxCyte Inc stock risky to hold now2026 News Drivers & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn

Apr 02, 2026

Mar 31, 2026

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 31, 2026

Mar 31, 2026

MaxCyte (MXCT) CEO awarded 600,000 options and 300,000 RSUs - stocktitan.net

Mar 31, 2026

Mar 31, 2026

New MaxCyte CFO gets 562,500-share inducement award under Nasdaq rule - stocktitan.net

Mar 31, 2026

Mar 31, 2026

RSI Check: Is now the right time to enter MaxCyte IncTrade Entry Report & Long-Term Growth Portfolio Plans - baoquankhu1.vn

Mar 31, 2026

Mar 31, 2026

MaxCyte (NASDAQ:MXCT) Upgraded by Wall Street Zen to Hold Rating - MarketBeat

Mar 31, 2026

Mar 29, 2026

Risk On: Will MaxCyte Inc outperform small cap indexes2026 Review & Risk Managed Investment Entry Signals - baoquankhu1.vn

Mar 29, 2026

Mar 28, 2026

MaxCyte sees Q4 core revenue between $6.6M and $6.7M - MSN

Mar 28, 2026

Mar 28, 2026

MaxCyte Appoints Parmeet Ahuja as New Chief Financial Officer to Drive Strategic Growth - Minichart

Mar 28, 2026

Mar 27, 2026

MaxCyte outlines $30M–$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlook - MSN

Mar 27, 2026

Mar 27, 2026

MaxCyte, Inc. (MXCT) reports Q4 loss, misses revenue estimates - MSN

Mar 27, 2026

Mar 27, 2026

MaxCyte Earnings Call Weighs Short‑Term Pain, Long‑Term Upside - The Globe and Mail

Mar 27, 2026

Mar 27, 2026

MaxCyte Appoints New Chief Financial Officer Ahuja - TipRanks

Mar 27, 2026

Mar 27, 2026

MaxCyte appoints Parmeet Ahuja as CFO, succeeding Douglas Swirsky - TradingView

Mar 27, 2026

Mar 27, 2026

New MaxCyte (NASDAQ: MXCT) CFO Parmeet Ahuja joins from Agilent - Stock Titan

Mar 27, 2026

Mar 27, 2026

Vanguard disaggregates holdings; reports 0% stake in MaxCyte (MXCT) - Stock Titan

Mar 27, 2026

Mar 27, 2026

MaxCyte Faces Nasdaq Delisting Risk as Share Price Slump Threatens Liquidity and Capital Access - TipRanks

Mar 27, 2026

Mar 27, 2026

MaxCyte, Inc. (NASDAQ:MXCT) Receives Average Rating of "Hold" from Brokerages - MarketBeat

Mar 27, 2026

Mar 26, 2026

MaxCyte ExPERT Platform: Leading Non-Viral Cell Engineering Technology for Next-Generation Cell & Gene Therapy Development - Minichart

Mar 26, 2026

Mar 25, 2026

MaxCyte 2025 10‑K: Revenue $33.0M, EPS $(0.42) - TradingView

Mar 25, 2026

Mar 25, 2026

MaxCyte (NASDAQ: MXCT) details 2025 losses and $2B SPL upside - Stock Titan

Mar 25, 2026

Mar 25, 2026

MXCT: Craig-Hallum Maintains Buy Rating but Lowers Price Target - GuruFocus

Mar 25, 2026

Mar 25, 2026

Craig-Hallum cuts MaxCyte stock price target on FY25 headwinds By Investing.com - Investing.com Australia

Mar 25, 2026

Mar 25, 2026

Craig Hallum Issues Pessimistic Forecast for MaxCyte (NASDAQ:MXCT) Stock Price - MarketBeat

Mar 25, 2026

Mar 25, 2026

Stifel cuts MaxCyte stock price target on 2026 revenue guidance - Investing.com

Mar 25, 2026

Mar 25, 2026

Craig-Hallum cuts MaxCyte stock price target on FY25 headwinds - Investing.com

Mar 25, 2026

Mar 25, 2026

Stifel cuts MaxCyte stock price target on 2026 revenue guidance By Investing.com - Investing.com Australia

Mar 25, 2026

Mar 25, 2026

MaxCyte 2025 Financial Results Review - AlphaStreet

Mar 25, 2026

Mar 25, 2026

MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 earnings call transcript - MSN

Mar 25, 2026

Mar 25, 2026

MaxCyte, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Mar 25, 2026

Mar 25, 2026

MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 Earnings Call Transcript - insidermonkey.com

Mar 25, 2026

Mar 25, 2026

MaxCyte Reports 2025 Financial Results, Announces 2026 Revenue Guidance and Expansion in Cell Therapy Platform 1 - Minichart

Mar 25, 2026

Mar 25, 2026

MaxCyte Inc (MXCT) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines Amid Strategic ... By GuruFocus - Investing.com Canada

Mar 25, 2026

Mar 24, 2026

MaxCyte, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - MarketScreener

Mar 24, 2026

Mar 24, 2026

MaxCyte, Inc. (MXCT) Announces Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget

Mar 24, 2026

Mar 24, 2026

MaxCyte (MXCT) Q4 2025 Earnings Call Transcript - The Globe and Mail

Mar 24, 2026

Mar 24, 2026

MaxCyte Q4 Earnings Call Highlights - MarketBeat

Mar 24, 2026

Mar 24, 2026

MaxCyte Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 24, 2026

Mar 24, 2026

MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Mar 24, 2026

Mar 24, 2026

Earnings call transcript: MaxCyte Q4 2025 misses earnings, revenue forecasts - Investing.com

Mar 24, 2026

Mar 24, 2026

Earnings call transcript: MaxCyte Q4 2025 misses earnings, revenue forecasts By Investing.com - Investing.com Australia

Mar 24, 2026

Mar 24, 2026

MaxCyte Reports Lower 2025 Revenue, Provides 2026 Outlook - TipRanks

Mar 24, 2026